IDEAYA Biosciences, Inc.
IDYANASDAQHealthcare● Active
$31.40
+$3.11(+10.98%)
Market Cap$2.8B
P/E Ratio—
52W High$39.28
52W Low$20.455
IDEAYA Biosciences, Inc. (IDYA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IDYA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$1.11
Est. -$1.07 · -3.7%
Revenue
$0.01B
Est. $0.01B · +30.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
IDYA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$1.09 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$1.07 | -$1.11 | -3.7% | $0.01B | $0.01B | +30.2% |
| ▲ Q1 FY2026 | Feb 17, 2026 | -$0.95 | -$0.94 | +1.2% | $0.01B | $0.01B | +72.5% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.95 | $1.33 | +240.6% | $0.21B | $0.01B | +3395.1% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.85 | -$0.88 | -3.5% | — | $0.00B | — |
| ▼ Q2 FY2025 | May 6, 2025 | -$0.75 | -$0.82 | -9.3% | — | $0.00B | — |
| ▼ Q1 FY2025 | Feb 13, 2025 | -$0.67 | -$1.49 | -122.4% | $0.01B | $0.00B | +180.6% |
| ▲ Q4 FY2024 | Nov 4, 2024 | -$0.67 | -$0.60 | +10.4% | — | $0.00B | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$1.09
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$1.11
EPS Est.
-$1.07
EPS Surpr.
-3.7%
Revenue
$0.01B
Q1 FY2026
Feb 17, 2026Beat
EPS Actual
-$0.94
EPS Est.
-$0.95
EPS Surpr.
+1.2%
Revenue
$0.01B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$1.33
EPS Est.
-$0.95
EPS Surpr.
+240.6%
Revenue
$0.21B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.88
EPS Est.
-$0.85
EPS Surpr.
-3.5%
Revenue
—
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.82
EPS Est.
-$0.75
EPS Surpr.
-9.3%
Revenue
—
Q1 FY2025
Feb 13, 2025Miss
EPS Actual
-$1.49
EPS Est.
-$0.67
EPS Surpr.
-122.4%
Revenue
$0.01B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
-$0.60
EPS Est.
-$0.67
EPS Surpr.
+10.4%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.87 | $-0.92 | $0.02 | 4 |
| Q3 FY2027 | $-1.81 | $-0.90 | $0.02 | 4 |
| Q2 FY2027 | $-2.20 | $-1.09 | $0.02 | 4 |
| Q1 FY2027 | $-2.25 | $-1.11 | $0.02 | 4 |
| Q4 FY2026 | $-2.21 | $-1.09 | $0.02 | 4 |
| Q3 FY2026 | $-1.31 | $-1.09 | $-0.72 | 10 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 5 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 8 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -3.7% | $28.90 | $28.80 | -0.35% |
| ▲ Q1 FY2026 | Feb 17, 2026 | +1.2% | $30.27 | $30.76 | +1.62% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +240.6% | $31.36 | $30.48 | -2.81% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -3.5% | $25.00 | $24.12 | -3.52% |
| ▼ Q2 FY2025 | May 6, 2025 | -9.3% | $20.47 | $17.75 | -13.29% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -122.4% | $21.95 | $20.76 | -5.42% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +10.4% | $28.60 | $30.00 | +4.90% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -23.6% | $36.99 | $36.00 | -2.68% |
Q2 FY2026-0.35%
Report Date
May 5, 2026
EPS Beat/Miss
-3.7%
Price Before
$28.90
Price After
$28.80
Q1 FY2026+1.62%
Report Date
Feb 17, 2026
EPS Beat/Miss
+1.2%
Price Before
$30.27
Price After
$30.76
Q4 FY2025-2.81%
Report Date
Nov 4, 2025
EPS Beat/Miss
+240.6%
Price Before
$31.36
Price After
$30.48
Q3 FY2025-3.52%
Report Date
Aug 5, 2025
EPS Beat/Miss
-3.5%
Price Before
$25.00
Price After
$24.12
Q2 FY2025-13.29%
Report Date
May 6, 2025
EPS Beat/Miss
-9.3%
Price Before
$20.47
Price After
$17.75
Q1 FY2025-5.42%
Report Date
Feb 13, 2025
EPS Beat/Miss
-122.4%
Price Before
$21.95
Price After
$20.76
Q4 FY2024+4.90%
Report Date
Nov 4, 2024
EPS Beat/Miss
+10.4%
Price Before
$28.60
Price After
$30.00
Q3 FY2024-2.68%
Report Date
Aug 6, 2024
EPS Beat/Miss
-23.6%
Price Before
$36.99
Price After
$36.00
Avg Beat Reaction+1.24%
Avg Miss Reaction-5.05%
Beat Rate3 / 8 quarters
Largest Move-13.29% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IDYA ends December
IDEAYA Biosciences, Inc. (IDYA) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-1.11 — missing the analyst consensus of $-1.07 by -3.7%. The next IDYA earnings date is expected around September 1, 2026.
Each quarter, investors track IDYA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IDYA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IDYA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IDYA earnings · 5 questionsIDEAYA Biosciences, Inc.'s next earnings report is expected around September 1, 2026. IDYA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IDYA historically reports after market close (AMC).
IDYA earnings datewhen is IDYA earningsIDYA next earnings datewhen does IDYA report earningsIDYA earnings calendar
▸ Source: FMP · IDEAYA Biosciences, Inc. SEC filings · US GAAP · IDEAYA Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026